{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"142"}]}],"title":"Any Treatment-Emergent Adverse Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"79"}]}],"title":"Any Treatment-Related Adverse Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"51"}]}],"title":"Any Adverse Event with Severity >= Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"20"}]}],"title":"Any Serious Adverse Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"7"}]}],"title":"Any Treatment-Related Serious Adverse Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"10"}]}],"title":"Treatment Discontinuation Due to Adverse Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"29"}]}],"title":"Any Laboratory Abnormalities Severity >=Grade 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"groups":[{"description":"brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion","id":"OG000","title":"Brentuximab Vedotin"},{"description":"placebo every 3 weeks by IV infusion","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Safety Analysis Set includes all patients who received at least 1 dose of brentuximab vedotin or only received placebo: 2 patients randomized to placebo received a single dose of brentuximab vedotin and are included in the brentuximab vedotin arm; 2 patients randomized to placebo received no study treatment and are not included in the analysis","reportingStatus":"POSTED","timeFrame":"Up to 12 months","title":"Incidence of Adverse Events or Laboratory Abnormalities","type":"SECONDARY","unitOfMeasure":"participants"}